Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

The FDA granted fast track designation to ND-L02-s0201 for two indications, liver fibrosis and cirrhosis secondary to NASH and liver fibrosis and cirrhosis secondary to hepatitis C infection.

Yes, metabolic dysfunction-associated steatohepatitis (MASH) can result in cirrhosis of the liver. Formerly known as nonalcoholic steatohepatitis (NASH), MASH describes a type of metabolic ...

Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis (NASH ... cirrhosis (F4) due to NASH, a form of non-alcoholic fatty ...

Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

The story begins with Etienne Sokal and Mustapha Najimi’s discovery of liver ... cirrhosis, fibrosis, and control the acute and sub chronic inflammation that respectively contributes to ACLF and ...

A study from Massachusetts General Hospital has found that growth hormone may help improve liver health in people with ...

due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events. The test is not for use in the diagnosis of NASH or for the ...

Nonalcoholic steatohepatitis (NASH) is a common disease that may progress to cirrhosis and liver failure. NASH is associated with overnutrition, obesity and insulin resistance. Genetic ...